WO2000044389A2 - Procede de preparation de vesicules membranaires - Google Patents
Procede de preparation de vesicules membranaires Download PDFInfo
- Publication number
- WO2000044389A2 WO2000044389A2 PCT/FR2000/000105 FR0000105W WO0044389A2 WO 2000044389 A2 WO2000044389 A2 WO 2000044389A2 FR 0000105 W FR0000105 W FR 0000105W WO 0044389 A2 WO0044389 A2 WO 0044389A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- membrane vesicles
- vesicles
- cells
- exosomes
- dendritic cells
- Prior art date
Links
- 239000012528 membrane Substances 0.000 title claims abstract description 98
- 238000000034 method Methods 0.000 title claims abstract description 77
- 210000004027 cell Anatomy 0.000 claims abstract description 57
- 239000012472 biological sample Substances 0.000 claims abstract description 35
- 238000005571 anion exchange chromatography Methods 0.000 claims abstract description 34
- 239000000523 sample Substances 0.000 claims abstract description 21
- 239000000427 antigen Substances 0.000 claims abstract description 15
- 108091007433 antigens Proteins 0.000 claims abstract description 15
- 102000036639 antigens Human genes 0.000 claims abstract description 15
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 8
- 210000001808 exosome Anatomy 0.000 claims description 89
- 238000002360 preparation method Methods 0.000 claims description 53
- 210000004443 dendritic cell Anatomy 0.000 claims description 49
- 239000012228 culture supernatant Substances 0.000 claims description 28
- 230000008569 process Effects 0.000 claims description 25
- 238000001914 filtration Methods 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 20
- 238000000108 ultra-filtration Methods 0.000 claims description 20
- 238000000746 purification Methods 0.000 claims description 18
- 238000001042 affinity chromatography Methods 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 238000004587 chromatography analysis Methods 0.000 claims description 12
- 238000005227 gel permeation chromatography Methods 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 150000001450 anions Chemical class 0.000 claims description 8
- 238000011210 chromatographic step Methods 0.000 claims description 8
- 238000012545 processing Methods 0.000 claims description 8
- 238000005352 clarification Methods 0.000 claims description 7
- 210000003630 histaminocyte Anatomy 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 6
- 238000005349 anion exchange Methods 0.000 claims description 5
- 239000013060 biological fluid Substances 0.000 claims description 5
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 4
- 210000001185 bone marrow Anatomy 0.000 claims description 4
- 210000005259 peripheral blood Anatomy 0.000 claims description 4
- 239000011886 peripheral blood Substances 0.000 claims description 4
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 210000002540 macrophage Anatomy 0.000 claims description 3
- 239000013592 cell lysate Substances 0.000 claims description 2
- 238000000464 low-speed centrifugation Methods 0.000 claims 1
- 238000002305 strong-anion-exchange chromatography Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 description 59
- 235000018102 proteins Nutrition 0.000 description 58
- 108090000623 proteins and genes Proteins 0.000 description 58
- 229920002684 Sepharose Polymers 0.000 description 33
- 239000000499 gel Substances 0.000 description 31
- 239000000243 solution Substances 0.000 description 24
- 238000005119 centrifugation Methods 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 239000000872 buffer Substances 0.000 description 14
- 239000000356 contaminant Substances 0.000 description 13
- 238000010828 elution Methods 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 238000000926 separation method Methods 0.000 description 11
- 239000007989 BIS-Tris Propane buffer Substances 0.000 description 10
- HHKZCCWKTZRCCL-UHFFFAOYSA-N bis-tris propane Chemical compound OCC(CO)(CO)NCCCNC(CO)(CO)CO HHKZCCWKTZRCCL-UHFFFAOYSA-N 0.000 description 10
- 230000001413 cellular effect Effects 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 239000008188 pellet Substances 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 210000001616 monocyte Anatomy 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 6
- 229920000936 Agarose Polymers 0.000 description 6
- 229920002307 Dextran Polymers 0.000 description 6
- 238000001493 electron microscopy Methods 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 238000005199 ultracentrifugation Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 108010088751 Albumins Proteins 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 5
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 description 4
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 4
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 4
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 230000009102 absorption Effects 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 238000001085 differential centrifugation Methods 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 239000012465 retentate Substances 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 108090000176 Interleukin-13 Proteins 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 208000016557 Acute basophilic leukemia Diseases 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 108020005199 Dehydrogenases Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 239000012506 Sephacryl® Substances 0.000 description 2
- 239000012505 Superdex™ Substances 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000002306 biochemical method Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000006167 equilibration buffer Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000001728 nano-filtration Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 101100243951 Caenorhabditis elegans pie-1 gene Proteins 0.000 description 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000004696 Poly ether ether ketone Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- -1 apoptotic bodies Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- JUPQTSLXMOCDHR-UHFFFAOYSA-N benzene-1,4-diol;bis(4-fluorophenyl)methanone Chemical compound OC1=CC=C(O)C=C1.C1=CC(F)=CC=C1C(=O)C1=CC=C(F)C=C1 JUPQTSLXMOCDHR-UHFFFAOYSA-N 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 239000013542 high molecular weight contaminant Substances 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000013541 low molecular weight contaminant Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 108700024542 myc Genes Proteins 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 235000008729 phenylalanine Nutrition 0.000 description 1
- 150000002994 phenylalanines Chemical class 0.000 description 1
- 229920002530 polyetherether ketone Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 235000017103 tryptophane Nutrition 0.000 description 1
- 150000003654 tryptophanes Chemical class 0.000 description 1
- 235000002374 tyrosine Nutrition 0.000 description 1
- 150000003668 tyrosines Chemical class 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/34—Size selective separation, e.g. size exclusion chromatography, gel filtration, permeation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
- B01D15/363—Anion-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J41/00—Anion exchange; Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
- B01J41/20—Anion exchangers for chromatographic processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
Definitions
- the present invention relates to a new process for the preparation (in particular the isolation and / or purification) of membrane vesicles.
- the invention also relates to the membrane vesicles thus prepared, as well as their biological and medical uses, for example.
- the membrane vesicles are vesicles, with a diameter generally less than 100 nm, composed of a lipid bilayer containing a cytosolic fraction.
- Specific membrane vesicles are more specifically derived from intracellular compartments, by fusion with the plasma membrane of a cell, leading to their release into biological fluids or into the supernatant of cells in culture.
- Such vesicles are generally designated by the term exosome.
- Exosomes generally have a diameter of between approximately 50 and 90 nm, more particularly between approximately 60 and 80 nm, and advantageously carry membrane proteins (in particular proteins of the major histocompatibility complex) which are in the same orientation as in the membrane. the cells from which they are derived.
- the exosomes contain membrane proteins such as CD40, CD80, HSP70 and are devoid of endoplasmic reticulum and golgi apparatus.
- exosomes have been demonstrated from different cell types, in various physiological contexts.
- B lymphocytes release exosomes carrying molecules of the major histocompatibility class II complex, which play a role in antigen presentation (Raposo et al., J. Exp. Med. 183 (1996) 1161).
- dendritic cells produce exosomes (also called dexosomes), having particular structural and functional characteristics, and playing a role in mediating the immune response, in particular in stimulating cytotoxic T lymphocytes. (Zitvogel et al., Nature Medicine 4 (1998) 594).
- tumor cells secrete, in a regulated manner, specific exosomes (also designated texosomes), carriers of tumor antigens and capable of presenting these antigens or of transmitting them to the antigen-presenting cells (patent application No. WO99 / 03499). It is also known that mast cell cells accumulate molecules in the intracellular vesicular compartments, which can be secreted under the effect of signals (Smith and Weis, Immunology Today 17 (1996) 60).
- the purity levels of the exosomes are satisfactory insofar as such preparations have made it possible to demonstrate the biological activity and the anti-tumor properties in animal models.
- these previous methods of preparation by centrifugation do not allow fine separation of the membrane vesicles (e.g., exosomes) from cellular proteins or certain macromolecular components (DNA, RNA) or macromolecular complexes. These methods therefore do not exclude the presence of unidentified contaminating biological agents which are incompatible with therapeutic use in humans.
- these stages are difficult to extrapolate on an industrial scale, in particular when large volumes have to be treated, or for autologous ex vivo applications (i.e., patient by patient), where the process must generally be implemented in a confined system.
- the present invention now provides a solution to this problem.
- the invention indeed describes new methods allowing the preparation (that is to say the isolation and / or purification) of membrane vesicles under conditions compatible with industrial use and pharmacological applications.
- the methods of the invention can be applied both for individualized preparations of autologous exosomes, and for preparations of exosomes obtained from established cell lines, for experimental, biological uses or for the purposes of Prophylactic or therapeutic vaccinations, for example.
- the present invention is based more particularly on the use of separation methods by chromatography for the preparation of membrane vesicles, and in particular for separating the membrane vesicles from possible contaminating biological entities.
- a first object of the invention resides in a process for the preparation of membrane vesicles from a biological sample characterized in that it comprises at least one step of treatment of the sample by anion exchange chromatography .
- the membrane vesicles in particular the exosomes, can be purified by anion exchange chromatography.
- the exosomes are resolved into a homogeneous peak after anion exchange chromatography. This result is completely unexpected insofar as the exosomes are complex supramolecular objects composed inter alia of a membrane surrounding an internal volume comprising inter alia soluble proteins.
- exosomes contain membrane proteins.
- a more particular object of the invention therefore relates to a process for the preparation, in particular for the purification of membrane vesicles from a biological sample, comprising at least one step of anion exchange chromatography.
- the chromatography is carried out under pressure. It can thus be more particularly a high performance liquid chromatography (HPLC).
- HPLC high performance liquid chromatography
- Different types of supports can be used for carrying out anion exchange chromatography. Mention may more preferably be made of cellulose, poly (styrene-divinylbenzene), agarose, dextran, acrylamide, silica, the ethylene glycol-methacrylate copolymer, or mixtures, for example agarose-dextran mixtures.
- the invention therefore relates to a process for the preparation of membrane vesicles from a biological sample, comprising at least one step during which the biological sample is treated by exchange chromatography.
- anions on a support chosen from cellulose, poly (styrene-divinylbenzene), silica, acrylamide, agarose, dextran, ethylene glycol-methacrylate copolymer, alone or in mixtures, optionally functionalized.
- supports in the form of beads.
- these are beads having a homogeneous and calibrated diameter, and having a sufficiently high porosity to allow the penetration of the objects to be chromatographed (Le., Exosomes).
- the diameter of the exosomes generally between 50 and 100 nm
- gels of high porosity in particular between approximately 10 nm and 5 ⁇ m, more preferably between approximately 20 nm and approximately 2 ⁇ m, even more preferably between approximately 100 nm and approximately 1 ⁇ m.
- the support used must be functionalized by means of a group capable of interacting with an anionic molecule.
- this group consists of an amine which can be ternary or quaternary which respectively defines a weak or strong anion exchanger.
- a strong anion exchanger In the context of the present invention, it is particularly advantageous to use a strong anion exchanger.
- a chromatography support as indicated above, functionalized with quaternary amines.
- the anion exchange chromatography is therefore carried out on a support functionalized with a quaternary amine.
- it is a support chosen from poly (styrene-divinylbenzene), acrylamide, agarose, dextran and silica, alone or in mixtures, functionalized with a quaternary amine.
- examples include Source Q, Mono Q, Q Sepharose, Poros HQ and Poros QE gels, Fractogel TMAE type gels, and Toyopearl Super Q gels.
- a particularly preferred support for carrying out anion exchange chromatography comprises poly (styrene-divinylbenzene).
- An example of this type of gel which can be used in the context of the invention is the Source Q gel, in particular Source 15 Q (Pharmacia).
- This support has the advantage of very large internal pores, thus offering little resistance to the circulation of liquid through the gel, while allowing rapid diffusion of the exosomes towards the functional groups, parameters which are particularly important in the case of the exosomes given their cut.
- the elution of the biological compounds retained on the column can be done in different ways, and in particular by means of the passage of an increasing concentration gradient of a saline solution, for example from 0 to 2 M. It is possible in particular to use a sodium chloride solution, in concentrations ranging from 0 to 2M, for example. Detection of different fractions as well purified is done by measuring their optical density (OD) at the column outlet by means of a continuous spectrophotometric reading. As an indication, under the conditions used in the examples, the fractions comprising the membrane vesicles were eluted at an ionic strength of between 350 and 700 mM approximately, depending on the types of vesicles.
- Different types of columns can be used to carry out this chromatographic step, depending on the needs and the volumes to be treated.
- a column of approximately 100 ⁇ l up to 10 ml or more it is possible to use a column of approximately 100 ⁇ l up to 10 ml or more.
- the supports available have a capacity which can reach, for example, 25 mg of proteins / ml.
- a 100 ⁇ l column has a capacity of the order of 2.5 mg of proteins which, taking into account the samples considered, can make it possible to treat culture supernatants of approximately 2 1 (which, after concentration of (a factor 10 to 20 for example, represent volumes of 100 to 200 ml per preparation). It is understood that higher volumes can also be treated, by increasing the volume of the column for example.
- a gel permeation chromatography step is added to the anion exchange step, either before or after the exchange chromatography step of 'anions.
- the permeation chromatography step takes place after the anion exchange step.
- the anion exchange chromatography step is replaced by the gel permeation chromatography step.
- a support preferably chosen from silica, acrylamide, agarose, dextran, ethylene glycol-methacrylate copolymer, or mixtures, for example mixtures, is preferably used.
- agarose-dextran By way of illustration, for gel permeation chromatography, a support such as Superdex 200HR (Pharmacia), TSK G6000 (TosoHaas) or even Sephacryl S (Pharmacia) is advantageously used.
- the method of the invention can be implemented from different biological samples.
- it may be a biological fluid originating from a subject (bone marrow, peripheral blood, etc.), a culture supernatant, a cell lysate, a prepurified solution, or any other composition comprising membrane vesicles.
- the biological sample is a culture supernatant of cells producing membrane vesicles.
- the biological sample is treated, prior to the chromatographic step, to be enriched in membrane vesicles (enrichment step).
- the present invention relates to a process for the preparation of membrane vesicles from a biological sample characterized in that it comprises at least: b) a step of enriching the sample with vesicles membranes, and, c) a step of processing the sample by anion exchange chromatography and / or by gel permeation chromatography.
- the biological sample is a culture supernatant treated so as to be enriched in membrane vesicles.
- the biological sample can consist of a prepurified solution obtained from a culture supernatant from a population of cells producing membrane vesicles or from a biological fluid by treatments such as centrifugation, clarification, ultrafiltration, nanofiltration and / or affinity chromatography, in particular by clarification and / or ultrafiltration and / or affinity chromatography.
- a preferred process for the preparation of membrane vesicles within the meaning of the present invention therefore more particularly comprises the following steps: a) culturing a population of cells producing membrane vesicles (eg of exosomes) under conditions allowing the release of the vesicles , b) a step of enriching the sample with membrane vesicles, and, c) a step of treating the sample by anion exchange chromatography and / or by gel permeation chromatography.
- the step for enriching the sample may comprise one or more steps of centrifugation, clarification, ultrafiltration, nanofiltration and / or affinity chromatography of the supernatant.
- the enrichment step comprises (i) a step of eliminating cells and / or cellular debris (clarification step), optionally followed by (ii) a concentration step and / or affinity chromatography.
- the enrichment step comprises a step of affinity chromatography, optionally preceded by a step of elimination of cells and / or cellular debris (clarification step).
- a preferred enrichment phase according to the invention comprises (i) a step of eliminating cells and / or cellular debris, (ii) a concentration and (iii) an affinity chromatography.
- the removal of cells and / or cellular debris can be carried out for example by centrifuging the sample at a low speed, preferably less than 1000 g, for example between 100 and 700 g.
- Preferred centrifugation conditions during this step are approximately 300g or 600g, for a period of between 1 and 15 minutes for example.
- the elimination of cells and / or cellular debris can also be carried out by filtration of the sample, possibly in combination with the centrifugation described above.
- Filtration can be carried out in particular by successive filtrations by means of filters having a decreasing porosity.
- filters with a porosity greater than 0.2 ⁇ m are preferably used, for example between 0.2 and 10 ⁇ m. It is possible in particular to use a succession of filters having a porosity of 10 ⁇ m, 1 ⁇ m, 0.5 ⁇ m then 0.22 ⁇ m.
- a concentration step can also be carried out, so as to reduce the volumes of sample to be treated during the chromatographic steps.
- the concentration can be obtained by centrifugation of the sample at high speeds, for example between 10,000 and 100,000 g, so as to pellet the membrane vesicles. In this regard, it can be a series of differential centrifugations, with the last centrifugation carried out around 70,000 g approximately.
- the membrane vesicles thus pelletized can then be taken up in a smaller volume and in an appropriate buffer for the subsequent stages of the process.
- the concentration step can also be carried out by ultrafiltration.
- This ultrafiltration makes it possible both to concentrate the supernatant and to carry out a first purification of the vesicles.
- the biological sample for example the supernatant
- Tangential ultrafiltration consists of concentrating and dividing a solution between two compartments (filtrate and retentate), separated by membranes of determined cutoff thresholds. The separation is carried out by application of a flow in the retentate compartment and of a transmembrane pressure between this compartment and the filtrate compartment.
- membranes with a cutoff threshold of less than 1000 kDa, preferably between 300 kDa and 1000 kDa, even more preferably between 300 kDa and 500 kDa, are used.
- the affinity chromatography step can be carried out in different ways, on different chromatographic materials and supports. It is advantageously a non-specific affinity chromatography, intended to retain certain contaminants present in the solution, without retaining the objects of interest (ie, the exosomes). It is therefore a negative selection. It is preferably a dye chromatography, making it possible to remove (ie, retain) contaminants such as proteins and enzymes, for example albumin, kinases, dehydrogenases, coagulation factors, interferons or lipoproteins , or co-factors, etc.
- the support used for this chromatography is a support as used for the ion exchange chromatography, functionalized with a dye.
- the dye can be chosen from Blue Sepharose (Pharmacia), Yellow 86, Green 5 and Brown 10 (Sigma).
- the support is more preferably agarose. It is understood that any other support and / or dye or reactive group making it possible to retain certain contaminants of the biological sample treated can be used within the framework of the present invention.
- the biological sample is obtained by treatment of a culture supernatant of cells producing membrane vesicles, by at least one filtration step.
- the biological sample is obtained by treatment of a culture supernatant of cells producing membrane vesicles, by at least one centrifugation step.
- the biological sample is obtained by treatment of a culture supernatant of cells producing membrane vesicles, by at least one ultrafiltration step.
- the biological sample is obtained by treatment of a culture supernatant of cells producing membrane vesicles, by at least one affinity chromatography step.
- a preferred method of more specific preparation of membrane vesicles within the meaning of the present invention comprises the following steps: a) culturing a population of cells producing membrane vesicles (eg of exosomes) under conditions allowing the release of the vesicles, b) the treatment of the culture supernatant to produce a biological sample enriched in membrane vesicles (eg in exosomes) by at least one step of ultrafiltration or affinity chromatography, and c) a step of processing the biological sample by anion exchange chromatography and / or gel permeation.
- step b) above comprises filtration of the culture supernatant, followed by ultrafiltration, preferably tangential.
- step b) above comprises a clarification followed by affinity chromatography on dye, in particular on Blue Sepharose.
- the harvested material can, if necessary, be subjected to one or more additional steps d) of treatment and / or filtration, in particular for the purpose of sterilization.
- filters preferably having a diameter less than or equal to 0.3 ⁇ m, even more preferably less than or equal to 0.25 ⁇ m, are preferably used.
- filters are for example filters with a diameter of 0.22 ⁇ m.
- the material obtained is for example distributed in suitable devices such as vials, tubes, bags, syringes, etc., in an appropriate storage medium.
- suitable devices such as vials, tubes, bags, syringes, etc.
- the purified vesicles thus obtained can be stored in the cold, frozen, or used extemporaneously.
- a particular preparation process within the meaning of the invention therefore comprises at least the following steps: c) a step of treatment of the biological sample by anion exchange chromatography and / or gel permeation and, d) a filtration step, in particular sterilizing filtration, of the material harvested after step c).
- the method of the invention comprises: c) a step of processing the biological sample by anion exchange chromatography, and, d) a step of filtration, in particular sterilizing filtration, of the material harvested after step c).
- the method of the invention comprises: c) a step of processing the biological sample by gel permeation chromatography, and, d) a step of filtration, in particular of sterilizing filtration, of the collected material after step c).
- the method of the invention comprises: c) a step of processing the biological sample by anion exchange chromatography followed or preceded by gel permeation chromatography, and, d) a filtration step, in particular sterilizing filtration, of the material harvested after step c).
- the membrane vesicles produced from dendritic cells (dexosomes) or certain texosomes are eluted at an ionic strength of between 500 and 700 mM approximately, and the vesicles of mast cells around 350 mM.
- the results presented in the examples also show that the method of the invention makes it possible to detect any contamination of the preparation with proteins predominant in the culture medium such as bovine serum albumin. Indeed, the chromatography of a standard bovine serum albumin solution under the preceding conditions shows that this gives rise to an eluted peak at a saline concentration distinct from that of the exosomes (FIG. N ° 3).
- the method of the invention therefore makes it possible (i) to purify membrane vesicles under conditions of quality and quantity compatible with pharmacological use, and (ii) to reveal the existence of distinct and contaminating biological entities within the biological sample processed.
- the process of the invention can be applied to the preparation of membrane vesicles of various origins.
- it may in particular be exosomes produced by cells presenting antigens, or by tumor cells, in particular.
- they may be primary cells, for example in culture, or also established lines, for example immortalized lines of cells producing membrane vesicles.
- They may be cells of mammalian origin, in particular of murine or human origin.
- the membrane vesicles are vesicles produced by cells presenting antigens, in particular dendritic cells, B lymphocytes, macrophages and mast cells, optionally after sensitization of these to one or more selected antigens.
- a particularly preferred application of the present invention lies in the preparation of membrane vesicles produced by dendritic cells.
- dendritic cells it may be human or animal dendritic cells, in particular human or murine.
- These cells can be primary cells, harvested from starting from a biological fluids of a subject or produced ex vivo from precursor cells, or also cells of established lines, for example immortalized with an oncogene (EP 701 604).
- a particular object of the present invention resides in a process for the preparation of membrane vesicles (dexosomes), characterized in that it comprises the following stages: a) obtaining a population of dendritic cells, b) culturing the cells dendritics under conditions allowing the production of membrane vesicles (dexosomes) and, c) purification of the membrane vesicles (dexosomes) by a process comprising at least one step of anion exchange chromatography, under the conditions defined above.
- a more preferred embodiment resides in a process for the preparation of dexosomes, characterized in that it comprises the following steps a) obtaining a population of dendritic cells, b) culturing the dendritic cells under conditions allowing the production of dexosomes, c) treatment of the culture supernatant to produce a biological sample enriched in dexosomes, in particular by at least an ultrafiltration or affinity chromatography step, and, d) purification of the dexosomes by a process comprising at least at least one step of anion exchange chromatography and / or gel permeation, under the conditions defined above.
- the dendritic cells are preferably obtained from a biological sample originating from a subject, for example from bone marrow or peripheral blood.
- a biological sample originating from a subject
- the techniques for producing dendritic cells have been described in the prior art and can be implemented by a person skilled in the art (see in particular the techniques described in application WO99 / 03499, incorporated herein by reference ).
- Dendritic cells can thus be prepared from stem cells of the immune system, from monocyte precursors or even isolated directly in differentiated form (Review by Hart, Blood 90 (1997) 3245).
- a preferred methodology in the context of the present invention is based on the production of dendritic cells from monocyte or bone marrow precursors. More particularly, it is preferred to use in the context of the present invention dendritic cells obtained by treatment of monocyte precursors (contained in blood or marrow) in the presence of a combination GM-CSF + IL4 or GM-CSF + IL-13 .
- a population of dendritic cells comprising immature dendritic cells.
- a population of dendritic cells is used which is composed mainly (i.e., at least 60%, preferably 70%) of immature dendritic cells.
- the step of obtaining dendritic cells can therefore advantageously comprise the preparation of a population of dendritic cells comprising immature dendritic cells, in particular of human origin, in particular from monocyte precursors, more particularly by treatment with a combination of cytokines such as GM-CSF + IL-4 or GM-CSF + IL-13.
- cytokines such as GM-CSF + IL-4 or GM-CSF + IL-13.
- immortalized dendritic cell populations can be immortalized dendritic cell lines (Dl line for example, or any other line produced for example by introduction of the myc oncogene into dendritic cells). It can also be dendritic cells prepared and then immortalized in vitro.
- the interest of immortalized dendritic cells lies in the constitution of banks of cells sensitized to groups of given antigens, which can be used industrially to prepare dexosomes capable of being administered to entire families of patients.
- the dendritic cells can be simply cultured under conventional conditions known to those skilled in the art.
- these cells are cultured under conditions which stimulate the production of dexosomes, in particular in the presence of factors capable of stimulating the production of dexosomes, in particular of a cytokine such as gamma interferon, interleukin-10 or l 'interleukin-12 (see for example application WO99 / 03499).
- the dendritic cells are therefore cultured, during step b) above, under conditions stimulating the production of membrane vesicles.
- the dendritic cells are sensitized to an antigen, prior to the production of the membrane vesicles.
- This embodiment thus makes it possible to charge the dendritic cells with particular antigen (s), so as to produce dexosomes having a given immunogenic character.
- Sensitization can be carried out by various techniques known per se, including, for example, bringing cells into contact with antigenic peptides, antigens, protein complexes, cells or membranes of cells expressing antigens, apoptotic bodies, membrane vesicles.
- sensitization is carried out by incubation with peptides, antigens, RNA or nucleic acids. It is understood that the present application is not limited to techniques for sensitizing or producing dendritic cells.
- Another particularly advantageous application of the present invention lies in the preparation of membrane vesicles produced by tumor cells, in particular human cells. It can in particular be any cell originating from a solid or liquid tumor as well as cells transformed or immortalized in vitro. Mention may more preferably be made of solid, hematopoietic or ascites tumors.
- a particular application of the present invention also lies in the preparation of membrane vesicles comprising one or more heterologous molecules, in particular recombinant molecules.
- membrane vesicles comprising one or more heterologous molecules, in particular recombinant molecules.
- the present invention can also make it possible to purify such modified vesicles.
- the invention can be applied to the preparation of membrane vesicles produced by any cell type, in particular exosome type vesicles, preferably having a diameter of less than about 100 nm. They may in particular be cells of macrophages, mast cells, reticulocytes, etc.
- exosome preparations from (i) cell lines such as tumor cell lines (TS / A), murine dendritic cell lines (Dl), mast cell line (RBL) and (ii) human dendritic cells derived from monocytes.
- TS / A tumor cell lines
- Dl murine dendritic cell lines
- RBL mast cell line
- human dendritic cells derived from monocytes The results obtained can be directly transposed to other primary cultures such as tumor cells, human dendritic cells, B lymphocytes, etc., cultivable under industrially acceptable conditions.
- the method of the invention can thus be implemented as a step of purifying exosomes in the context of their use in human therapy.
- the membrane vesicles thus obtained constitute, depending on their origin, tools for studying cancers or for regulating the immune system, for transferring molecules, for producing antibodies, for labeling, for diagnosis, for building up banks, principles vaccine or medication, etc.
- the process of the invention can also be used as a method for quality control on the possible presence of contaminants (in particular of contaminating proteins) in the culture medium or in preparations of membrane vesicles.
- the present invention can therefore be implemented both in a preparative method of membrane vesicles and in an analytical system making it possible to control the quality of a preparation of membrane vesicles, whatever their method of preparation.
- the present invention therefore also relates to a process for controlling the presence of contaminants, in particular of protein or nucleic origin, in a preparation of membrane vesicles, in particular of exosomes, comprising the treatment of a fraction of said preparation by a step at less anion exchange chromatography, and the detection of the presence of contaminants.
- the invention also relates, in general, to the use of anion exchange chromatography, in particular of the high performance liquid type, for the preparation or the purification of membrane vesicles. She relates to the use of affinity chromatography for the preparation or purification of membrane vesicles.
- a subject of the invention is also the membrane vesicles prepared by the process of the invention, as well as any composition comprising such vesicles.
- Figure 1 Elution profile after anion exchange chromatography of a sample of exosomes prepared by differential centrifugation.
- Figure 2 Analysis of the protein profile of the different elution fractions of an exosome preparation by electrophoresis in SDS PAGE then staining with Coomassie blue.
- Figure 3 Elution profile after anion exchange chromatography of a standard bovine serum albumin solution.
- Figure 4 Diagram of treatment of a biological sample comprising membrane vesicles by tangential ultrafiltration.
- Figure 5 General profile of the Blue sepharose 6 fast flow step after centrifugation at 600 and 10,000 g of a dexosome supernatant.
- Figure n ° 6 Western blot directed against the MHC II molecules of the exosomes, in the non-adsorbed fraction and in the eluate, from the Blue sepharose 6 fast flow step.
- Figure n ° 7 General profile of the 15Q source stage after a Blue sepharose fast flow stage.
- Figure 8 Details of the elution gradient on the 15Q source after a Blue sepharose 6 fast flow step (enlargement of the rectangular area at the bottom right in Figure 7).
- Figure 9 Example of a purification profile of exosomes produced from the RBL DR + line (equivalent to 53 ⁇ g of proteins) by a Source 15Q column after treatment with DNase and RNase.
- Figure n ° 10 Separation of exosomes by a discontinuous NaCl gradient on a Source 15Q support.
- the TS / A cell line is a murine cell line established from a spontaneous mammary carcinoma. This line is cultivated at 37 ° C. in the presence of 5% of CO 2 in RPMI medium in the presence of 10% of fetal calf serum (Dominique Dutcher).
- the dendritic cell lines are maintained in an IMDM medium containing 10% of inactivated fetal bovine serum, 2 mM of L-glutamine, 50 ⁇ M of 2- ⁇ ME, 100 IU / ml of penicillin, and 100 ⁇ g / ml of streptomycin.
- This example illustrates how an anion exchange chromatography step can be used to separate impurities from an exosome preparation.
- the starting material consists of a concentrate of exosomes prepared by differential centrifugation from a culture supernatant of TS / A cells making it possible to separate the exosomes from the cells or cellular debris present in the culture medium.
- the first centrifugation is carried out at low speed (300 g for 5 min) in order to pellet the cells in suspension present in the culture supernatant.
- Two other centrifugations (1200g for 20 minutes then 10,000g for 30 minutes) allow the cellular debris to be pelleted.
- the supernatant thus clarified is then subjected to a high speed ultracentrifugation of 70,000 g for 1 hour making it possible to pellet the exosomes.
- This preparation is then washed in a large volume of saline solution to be recentrifuged under the previous conditions. The pellet is then taken up in a volume of approximately 100 ⁇ l of saline solution and constitutes a concentrated solution of exosomes. The amount of protein is measured by the Bradford technique (Biorad, Ivry, France). This concentrate has a total protein content of between 500 and 1000 ⁇ g / ml. 40 ⁇ g of this preparation of exosomes diluted in 500 ⁇ l of Tris / HCL 50 mM pH buffer are injected into a column containing Source Q 15 gel (Pharmacia) balanced in a Tris / HCL solution 50 mM pH 8.
- the adsorbed species are eluted on 30 column volumes with a linear NaCl gradient from 0 to 500 mM, then with a 2M NaCl solution.
- the elution fractions are analyzed by spectrophotometry at 260 and 280 nm.
- the elution fractions are grouped into five major fractions (from FI to F5) in order to be able to analyze their respective protein profile.
- the proteins of each fraction are precipitated by 1/10 by volume of a 100% trichloroacetic acid solution and then rinsed with an acetone solution.
- the protein pellets are taken up in 20 ⁇ l of Laemmli solution, and are deposited on an SDS PAGE acrylamide gel which is then colored with Coomassie blue.
- the elution profiles at 260 and 280 nm are shown in FIG. 1.
- the profiles show the presence of 3 distinct symmetrical peaks, eluted at the respective saline concentrations of 105 mM, 400 mM and 2 M NaCl.
- the peak eluted (fraction F2) at 105 mM NaCl presents a different protein profile showing only two distinct bands.
- the absorbance measurements at 260 and 280 nm give a ratio of 1.6 suggesting the presence of a combination of nucleic acids and proteins.
- fraction F5 eluted at 2 molar of NaCl corresponds to the biological compounds strongly associated with the column. It is therefore possible to separate the exosomes from impurities by an anion exchange step.
- This anion exchange chromatography technique also makes it possible to evaluate the degree of contamination of an exosome preparation by the proteins present in the culture medium.
- chromatographing 10 ⁇ g of a bovine serum albumin solution corresponding to the majority protein of the culture medium, that this is eluted at 205 mM NaCl in the form of a narrow peak distinguishable from the peaks previously described. in the case of exosomes.
- Ultrafiltration can therefore be used in a process for purifying exosomes in order to separate them from contaminating proteins.
- the first buffer is a 100 mM Bis-Tris-Propane (BTP) solution (Sigma, 99%> purity), buffered at pH 6, this buffer is connected to channel A of the chromatograph (BioCad Sprint, Perkin-Elmer) .
- the second buffer is a 100 mM Bis-Tris-Propane solution, buffered to pH 9, this buffer is connected to channel B of the chromatograph.
- Water is produced on resin by a Milli-Q system with a resistance of 18 M ⁇ cm. the water is connected to channel C.
- a solution of sodium chloride (NaCl, Prolabo, 99.5%) purity) is connected to channel C. 3 M.
- Soda solution is connected to channel F NaOH, Prolabo, 98% minimum purity) 0.1 M.
- Lane E is used to load the culture supernatants on the columns. All buffers are made from water produced by the Milli-Q system, the buffers are not degassed.
- the first step is carried out with a column of Blue Sepharose 6 fast flow
- the matrix is agarose coupled with Blue sepharose 6 fast flow
- Blue 3 G (7%>).
- the particle size is between 45 and 165 ⁇ m.
- the maximum linear flow is 750 cm / hr.
- the gel is stable at pH between 4 and 12, at extreme pH 2 and 14, the gel can be damaged, which leads to a decrease in the fixing capacity (decoupling of Blue sepharose 6 fast flow) and an increase in pressure. (formation of fines).
- Blue Sepharose 6 fast flow is specific for components like albumin, kinases, dehydrogenases and other enzymes containing cofactors like NAD + , coagulation factors, interferons and lipoproteins.
- the column volume used is approximately 5.5 ml of gel (Cl 0/10, Pharmacia), ie a theoretical capacity of 80 to 110 mg of albumin serum.
- the flow rate used is 2 ml / min (150 cm / hr) on the BioCad Sprint and 3.5 ml / min (260 cm / hr) with a Pharmacia detection system.
- the pressure does not exceed 2.5 bars and is mainly due to the DO measurement cells
- the second step is carried out with a Source 15Q column (pharmacia), a strong anion exchanger.
- the matrix is polystyrene crosslinked with divinylbenzene.
- the size of the beads is 15 ⁇ m and is homogeneous.
- the beads are traversed by a network of pores with a size varying from 20 to 1000 nm.
- These gels are very resistant to pressure and accept high linear flow rates (1800 cm / hr and more) while keeping a satisfactory resolution and capacity. This is made possible thanks to the homogeneity of the beads and their porosity which increase the molecules' access to the functional groups.
- the gel is stable at pH between 2 and 12 beyond the gel may suffer significant damage which reduces its capacity.
- the theoretical binding capacity of this exchanger is approximately 25 mg of proteins per ml of gel.
- a 0.8 ml column is used (PEEK column 4.6 mm ID / 50 mm L, Perkin-Elmer), ie a maximum capacity of 20 mg of proteins.
- the actual capacity, which allows good resolution to be maintained, is around 10%) of this maximum capacity, ie 2 mg of protein.
- the flow rate used is 5 ml / min (1880 cm hr) and allows rapid separations.
- the column is packaged with the Poros selfPack system at 15ml / min at 150 bars.
- the BioCad is an HPLC system (High Performance Liquid Chromatography) which allows to work at high pressures (maximum 204 bars) and at flow rates ranging from 0.2 to 60 ml / min. You can connect up to 6 buffers (the 6 channels are currently used), and the system can be treated with 0.1 M sodium hydroxide (pH 12) for the depyrogenization of the tubing and the column.
- HPLC system High Performance Liquid Chromatography
- the separations can be carried out at ambient temperature or at 4 ° C.
- the samples are loaded either by one of the accessible routes or by injection loops for small volumes (from 100 ⁇ l to 5 ml).
- the detection system uses a double-channel UV cell: from 190 to 450 nm for UV and from 366 to 700 nm for the visible. Conventionally, detection at 254 nm is used for nucleic acids and detection at 280 nm for proteins (those are amino acids with a benzene ring such as tyrosines, tryptophanes and phenylalanines which absorb).
- the system is fully computer controlled (software developed by Perspective biosystem). For each separation, all the parameters (pressure, flow, conductivity, optical density, pH, etc.) can be checked. Finally, the separate sample is either recovered in a 50 ml Falcon tube or collected in silicone eppendorf tubes (Advantec SF-2120 collector) to minimize non-specific interactions.
- dendritic cells are obtained from monocytic precursors of peripheral blood.
- the isolated monocytes are cultured in the presence of a combination of GM-CSF and IL-13 or IL-4 (see the techniques described in application WO99 / 03499).
- GM-CSF GM-CSF
- IL-13 IL-4
- IL-4 see the techniques described in application WO99 / 03499.
- exosomes it is preferable to use a population of immature dendritic cells.
- the culture supernatants are centrifuged twice at 600 g and once at 10,000 g before being loaded onto the column of Blue Sepharose 6 fast flow.
- a 5.5 ml column is used, the flow rate is 2 ml / min (linear flow rate of 150 cm / h, contact time of 2.7 min), the pressure is around 2.5 bars ( fig 5).
- the column is equilibrated in 12 mM BTP buffer, 150 mM NaCl and pH 7. After equilibration, the supernatant is loaded onto the column and then this is washed with the same equilibration buffer until the DO goes down again Elution fixed proteins are produced in 12 mM BTP, 1.5 M NaCl and pH 7 (in 3 to 4 column volumes).
- the column is regenerated by passing water (2 to 3 column volumes), then 2 volumes of 0.1 M sodium hydroxide (pH 12) are passed, finally, the column is rebalanced in 12 mM BTP, 150 mM NaCl and pH 7. Quantitative and qualitative aspect of the Blue sepharose 6 fast flow stage:
- the Blue sepharose 6 fast flow step is specific for proteins such as albumin, which is a major contaminant of the culture supernatant.
- the protein concentration of each fraction of the Blue sepharose 6 fast flow step is measured by a Biorad technique (measurement of an OD at 600 nm). The results are collated in Table 1.
- the non-adsorbed fraction represents only 7 to 10% of the total proteins loaded on the column of Blue Sepharose 6 fast flow.
- the step is specific for major contaminants of the supernatant.
- each fraction is deposited on an SDS-PAGE gel in a reducing condition and stained with silver nitrate.
- the overload of the column 50 ml of supernatant loaded on a column of Blue sepharose 6 fast flow of 5.5 ml
- the percentage of the non-adsorbed fraction increases from 7 to more than 30% of the amount of protein loaded.
- This value is between 16 and 18 mg of protein per ml of Blue Sepharose 6 fast flow gel.
- 1 ml of Blue Sepharose 6 fast flow gel makes it possible to purify approximately 5 to 6 ml of culture supernatant (AIMV 2.5%> of HSA). This value becomes important for the study of scale up since it determines the size of the column to be used and therefore the cost of this step.
- the major contaminant of the culture supernatants is albumin. This contaminant is found, after fixing on the Blue Sepharose 6 fast flow, in the eluate and regeneration fractions. In addition to this contaminant, there are many other low and high molecular weight contaminants.
- the Blue sepharose 6 fast flow stage allows the elimination of approximately 90 to 95%> of the contaminants from the culture supernatant.
- the exosomes are in the non-adsorbed fraction of Blue sepharose 6 fast flow (fig. 6).
- Anion exchanger stage source 15Q (Pharmacia). Using a 0.8 ml 15Q source column with a flow rate of 5 ml / min (linear flow rate of 1880 cm / h, contact time 0.1 min) with a pressure of the order of 50 bars. The non-adsorbed fraction of Blue Sepharose 6 fast flow is directly loaded on the 15Q source (fig. 7) without changes in the saline concentration (NaCl) or the pH.
- the column is washed in 12 mM BTP buffer, 280 mM NaCl at pH 7 (35 column volumes) until the DO drops to values close to 0.
- a second washing step is carried out. at a saline concentration of 150 mM NaCl (10 column volumes) to reinforce the interactions of the exosomes with the support.
- a first gradient of 150 to 420 mM NaCl is produced in 7 column volumes (FIG. 8) then the gradient is stopped for 9 column volumes.
- the second gradient starts from 420 mM NaCl to 1 M NaCl in 25 column volumes.
- the exosomes are eluted in this second gradient in two peaks at 550 and 700 mM NaCl (fig. 8).
- the column is regenerated by passing 10 volumes of water column then by 10 volumes of 0.1 M sodium hydroxide column (pH 12) and finally by passing 10 column volumes of 3M NaCl.
- the column is then equilibrated in 12 mM BTP buffer, 150 mM NaCl, pH 7.
- Source 15Q is capable of fixing approximately 25 mg of protein (manufacturer's data), i.e. for the 0.8 ml, 20 mg of protein. It is clear that we are very far from the maximum of the column and from 5 to 10% in agreement with good resolution, since these values are between 1 and 2 mg of proteins.
- each elution peak is ultracentrifuged (100,000 g for 1 hour) and pooled to be observed by electron microscopy.
- the first peak eluted between 150 and 420 mM NaCl
- the second peak eluted at 550 mM NaCl
- shows a lower background noise a much larger number of vesicles marked with an anti MHC II antibody, there is also heterogeneity in the size of the vesicles.
- the third peak (eluted at 700 mM NaCl) no longer exhibits background noise, the vesicles are practically all marked with an anti-MHC II antibody and are much more homogeneous in size.
- exosomes produced from the RBL (Rat Basophilic Leukemia) line Purification by HPLC of exosomes produced from the RBL (Rat Basophilic Leukemia) line.
- the exosomes are produced from a RBL line (Rat Basophilic Leukemia) transfected in a stable manner to express, on the exosome membrane, molecules of the human MHC II (PCT / FR99 / 02691). After induction, by an ionophore (iomicyne), the cells degranulate and release exosomes in a protein-free medium (RPMI). After removal of cells by centrifugation at
- the treated supernatants are then centrifuged at 10,000 g at 37 ° C, 30 min, then at
- the column is equilibrated in 12 mM Bis-Tris-Propane (BTP) buffer, 150 mM NaCl and pH 7. After loading the sample, the column is washed with 15 to 20 column volumes of the same equilibration buffer. Elution is carried out with 25 column volume by varying the salt concentration from 150 mM to 1 M NaCl, the pH is kept constant (FIG. 9). The medium is very little contaminated with proteins since the cells are washed in PBS and the induction as well as the release of the exosomes is done in RPMI alone. This is confirmed by the low absorption observed (280 and 254 nm) in the non-adsorbed fraction of Source 15Q.
- BTP Bis-Tris-Propane
- peak 1 which has a signal intensity, in proteins, 7 to 8 times less than peak 2 has a western blot signal equivalent to that of peak 2. This may reflect a higher purity of peak 1
- the peaks were ultracentrifuged and observed by electron microscopy.
- Peak 1 is very rich in exosomes labeled with an anti-human MHC II antibody, there is little or no background noise.
- the exosomes are heterogeneous in size, there does not seem to be any separation of the exosomes not by their size but by a specific mechanism of competition between the eluent (NaCl) and the exosomes.
- NaCl eluent
- the fractions between the two peaks were analyzed by electron microscopy. There are few exosomes there with a higher background noise than in peak 1.
- Peak 2 is very similar to the fractions between the two peaks, there are few exosomes and greater background noise.
- Source 15Q is capable of retaining exosomes and separating them from possible contaminants (fig. 9).
- the vast majority of exosomes are eluted in the same peak at 350 mM NaCl.
- the heterogeneity of the size of the exosomes seems to indicate that the separation is based on ionic exchanges and not on sieving.
- Source 15Q can therefore be used as a purification step for RBL exosomes.
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL14369200A IL143692A0 (en) | 1999-01-27 | 2000-01-19 | Methods for preparing membrane vesicles |
EA200100819A EA003235B1 (ru) | 1999-01-27 | 2000-01-19 | Способ получения мембранных пузырьков |
US09/890,319 US6899863B1 (en) | 1999-01-27 | 2000-01-19 | Method for preparing membrane vesicles |
EP00900609A EP1143982A2 (fr) | 1999-01-27 | 2000-01-19 | Procede de preparation de vesicules membranaires |
CA002360752A CA2360752A1 (fr) | 1999-01-27 | 2000-01-19 | Procede de preparation de vesicules membranaires |
AU30561/00A AU768322B2 (en) | 1999-01-27 | 2000-01-19 | Method for preparing membrane vesicles |
JP2000595691A JP2002535665A (ja) | 1999-01-27 | 2000-01-19 | 膜小胞を調製するための方法 |
HK02102905.8A HK1042647A1 (zh) | 1999-01-27 | 2002-04-17 | 製備膜囊的方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9900886A FR2788780B1 (fr) | 1999-01-27 | 1999-01-27 | Procede de preparation de vesicules membranaires |
FR99/00886 | 1999-01-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000044389A2 true WO2000044389A2 (fr) | 2000-08-03 |
WO2000044389A3 WO2000044389A3 (fr) | 2000-11-16 |
Family
ID=9541269
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2000/000105 WO2000044389A2 (fr) | 1999-01-27 | 2000-01-19 | Procede de preparation de vesicules membranaires |
Country Status (11)
Country | Link |
---|---|
US (1) | US6899863B1 (fr) |
EP (1) | EP1143982A2 (fr) |
JP (1) | JP2002535665A (fr) |
CN (1) | CN1355704A (fr) |
AU (1) | AU768322B2 (fr) |
CA (1) | CA2360752A1 (fr) |
EA (1) | EA003235B1 (fr) |
FR (1) | FR2788780B1 (fr) |
HK (1) | HK1042647A1 (fr) |
IL (1) | IL143692A0 (fr) |
WO (1) | WO2000044389A2 (fr) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003016522A2 (fr) | 2001-08-17 | 2003-02-27 | Anosys, Inc. | Procedes et composes pour le ciblage de proteines vers des exosomes |
EP1766053A2 (fr) * | 2004-06-02 | 2007-03-28 | Sourcepharm, Inc. | Microvesicules contenant de l'arn et methodes associees |
WO2013079701A2 (fr) | 2011-11-30 | 2013-06-06 | University Of Bremen | Expression d'arnmi dans le tissu placentaire |
WO2017149118A1 (fr) | 2016-03-03 | 2017-09-08 | Institut Gustave Roussy | Vaccins à base de pioneer translation products (ptp) contre le cancer |
CN108025027A (zh) * | 2015-06-12 | 2018-05-11 | 哈德逊医学研究中心 | 一种治疗方法 |
US10231997B2 (en) | 2012-08-15 | 2019-03-19 | The University Of Chicago | Exosome-based therapeutics against neurodegenerative disorders |
WO2019081474A1 (fr) * | 2017-10-24 | 2019-05-02 | Evox Therapeutics Limited | Purification par affinité de vésicules extracellulaires modifiées |
WO2019238626A1 (fr) | 2018-06-12 | 2019-12-19 | Evox Therapeutics Ltd | Ingénierie de vésicules extracellulaires pour une purification par affinité |
WO2022003206A1 (fr) | 2020-07-03 | 2022-01-06 | Evox Therapeutics Ltd | Vésicules extracellulaires à demi-vie améliorée |
WO2022229220A1 (fr) | 2021-04-26 | 2022-11-03 | Evox Therapeutics Limited | Vésicules extracellulaires (ev) modifiées à demi-vie améliorée |
Families Citing this family (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8021847B2 (en) | 2004-06-02 | 2011-09-20 | Proxy Life Science Holdings, Inc. | Microvesicle-based compositions and methods |
US8758991B2 (en) * | 2006-04-26 | 2014-06-24 | University Of Louisville Research Foundation, Inc. | Isolation of membrane vesicles from biological fluids and methods of using same |
CN101641010A (zh) * | 2007-01-26 | 2010-02-03 | 路易斯维尔大学研究基金会公司 | 用作疫苗的外来体组分的修饰 |
CA2733672C (fr) | 2007-08-16 | 2018-09-11 | The Royal Institution For The Advancement Of Learning/Mcgill University | Microvesicules issues d'une cellule tumorale |
US20100255514A1 (en) | 2007-08-16 | 2010-10-07 | The Royal Institution For The Advancement Of Learning/Mcgill University | Tumor cell-derived microvesicles |
SG190670A1 (en) | 2008-02-01 | 2013-06-28 | Gen Hospital Corp | Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions |
US20220162704A1 (en) * | 2008-02-01 | 2022-05-26 | The General Hospital Corporation | Methods of preparing microvesicle micrornas from bodily fluids |
US11266736B2 (en) | 2008-04-17 | 2022-03-08 | Vin De Bona Trading Company Pte Ltd | Method of painting micro vesicles |
CN102308004A (zh) | 2008-10-30 | 2012-01-04 | 卡里斯生命科学卢森堡控股有限责任公司 | 评价rna图案的方法 |
CN107254538A (zh) | 2008-11-12 | 2017-10-17 | 卡里斯生命科学瑞士控股有限责任公司 | 使用外来体来确定表现型的方法和系统 |
EP2454588B1 (fr) | 2009-07-16 | 2015-07-15 | The General Hospital Corporation | Analyse d'acides nucléiques |
US20130029339A1 (en) | 2009-09-09 | 2013-01-31 | The General Hospital Corporation | Use of microvesicles in analyzing kras mutations |
WO2011031877A1 (fr) | 2009-09-09 | 2011-03-17 | The General Hospital Corporation | Utilisation de microvésicules dans l'analyse de profils d'acide nucléique |
WO2011053257A2 (fr) | 2009-11-02 | 2011-05-05 | Agency For Science, Technology And Research (A*Star) | Procédés de surveillance d'états cellulaires |
WO2011066589A1 (fr) | 2009-11-30 | 2011-06-03 | Caris Life Sciences Luxembourg Holdings | Procedes et systemes pour isoler, stocker et analyser des vesicules |
WO2011097480A1 (fr) * | 2010-02-05 | 2011-08-11 | University Of Louisville Research Foundation, Inc. | Compositions exosomales et procédés pour le traitement de maladies |
US9128101B2 (en) | 2010-03-01 | 2015-09-08 | Caris Life Sciences Switzerland Holdings Gmbh | Biomarkers for theranostics |
JP2013526852A (ja) | 2010-04-06 | 2013-06-27 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス | 疾患に対する循環バイオマーカー |
WO2012006476A2 (fr) | 2010-07-07 | 2012-01-12 | Aethlon Medical, Inc. | Procédés et compositions permettant de quantifier des exosomes |
US20140045915A1 (en) | 2010-08-31 | 2014-02-13 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
US20130295574A1 (en) | 2010-11-10 | 2013-11-07 | Exosome Diagnostics, Inc. | Method for Isolation of Nucleic Acid Containing Particles and Extraction of Nucleic Acids Therefrom |
US20140004601A1 (en) * | 2010-12-20 | 2014-01-02 | Agency For Science, Technology And Research | Method of purifying exosomes |
WO2012155014A1 (fr) | 2011-05-11 | 2012-11-15 | Exosome Diagnostics, Inc. | Extraction d'acide nucléiques à partir de matériaux biologiques hétérogènes |
AU2012272908A1 (en) | 2011-06-21 | 2013-12-19 | Alnylam Pharmaceuticals, Inc. | Assays and methods for determining activity of a therapeutic agent in a subject |
GB201110777D0 (en) * | 2011-06-24 | 2011-08-10 | Aqua Bio Technology Asa | Methods and uses |
GB201110783D0 (en) | 2011-06-24 | 2011-08-10 | Aqua Bio Technology Asa | Methods and uses |
ES2395793B1 (es) * | 2011-07-28 | 2013-12-27 | Consejo Superior De Investigaciones Científicas (Csic) | Procedimiento de obtención y usos de vesículas de membrana de un organismo marino para su utilización industrial. |
WO2013028788A1 (fr) | 2011-08-22 | 2013-02-28 | Exosome Diagnostics, Inc. | Marqueurs biologiques d'urine |
WO2013071239A1 (fr) | 2011-11-10 | 2013-05-16 | Exosome Diagnostics, Inc. | Dosage du liquide céphalorachidien |
CN103479682B (zh) * | 2012-06-14 | 2015-03-11 | 苏州恒宇生物科技有限公司 | 一种植物来源活性成分-纳米级膜性囊泡的制备方法 |
US10488403B2 (en) * | 2012-07-19 | 2019-11-26 | Atlantic Cancer Research Institute | Method for the isolation of microvesicles |
AU2013291761B2 (en) * | 2012-07-19 | 2018-03-15 | Reneuron Limited | Stem cell microparticles |
CA2883220C (fr) | 2012-08-30 | 2022-09-20 | Exosome Diagnostics, Inc. | Temoins pour dosages d'acide nucleique |
CN105025878A (zh) | 2012-10-03 | 2015-11-04 | 外来体诊断公司 | 微泡在医学疾病和病况的诊断、预后和治疗中的用途 |
US20150233800A1 (en) | 2012-10-11 | 2015-08-20 | Vin-De-Bona Trading Company Pte Ltd | Method of painting microvesicles |
US10942184B2 (en) | 2012-10-23 | 2021-03-09 | Caris Science, Inc. | Aptamers and uses thereof |
BR112015016136A2 (pt) | 2013-01-03 | 2017-07-11 | Exosome Diagnostics Inc | métodos para isolar microvesículas |
EP2971282B1 (fr) | 2013-03-14 | 2018-09-19 | Pioma Inc. | Histone h2ax microvésiculaire en tant que biomarqueur pour le stress génotoxique |
SG11201508433TA (en) * | 2013-04-12 | 2015-11-27 | Andaloussi Samir El | Therapeutic delivery vesicles |
AU2014305994B2 (en) | 2013-08-06 | 2019-02-21 | Exosome Diagnostics, Inc. | Urine biomarker cohorts, gene expression signatures, and methods of use thereof |
GB201317887D0 (en) | 2013-10-09 | 2013-11-20 | Reneuron Ltd | Product |
WO2015031694A2 (fr) | 2013-08-28 | 2015-03-05 | Caris Science, Inc. | Sondes oligonucléotidiques et leurs utilisations |
EP3052616A4 (fr) * | 2013-10-02 | 2017-03-29 | Paradigm Biopharmaceuticals Limited | Procédé de production d'exosomes |
CN105658782B (zh) | 2013-10-25 | 2018-08-07 | 凸版印刷株式会社 | 膜囊泡回收设备、膜囊泡回收方法及膜囊泡分析方法 |
FR3014198B1 (fr) * | 2013-12-03 | 2017-03-03 | Biomerieux Sa | Procede d'isolement d'exosomes |
EP3081223B1 (fr) * | 2013-12-12 | 2020-02-19 | Samsung Life Public Welfare Foundation | Procédé pour favoriser la génération d'exosome dérivé de cellule souche à l'aide de thrombine |
EP3120857B1 (fr) | 2014-03-18 | 2021-02-17 | Samsung Life Public Welfare Foundation | Compositions pour leur utilisation dans le traitement d'une maladie inflammatoire du cerveau comprenant des exosomes dérivés de cellules souches en tant que principe actif |
WO2015153732A2 (fr) | 2014-04-01 | 2015-10-08 | Cornell University | Utilisation d'adn double brin dans des exosomes : un nouveau biomarqueur dans la détection du cancer |
US11268085B2 (en) | 2014-05-27 | 2022-03-08 | Exosome Diagnostics, Inc. | Methods for isolating microvesicles and extracting nucleic acids from biological samples |
KR102421185B1 (ko) | 2014-07-09 | 2022-07-14 | 엑소좀 디아그노스틱스, 인크. | 생물학적 샘플로부터 미세소포체를 단리시키고 핵산을 추출하는 방법 |
US20170227541A1 (en) | 2014-07-17 | 2017-08-10 | The Trustees Of The University Of Pennsylvania | Methods for using exosomes to monitor transplanted organ status |
WO2016013660A1 (fr) | 2014-07-24 | 2016-01-28 | 凸版印刷株式会社 | Structure de membrane lipidique, support d'immobilisation de structure de membrane lipidique, et procédé de fusion de cellules |
EP3112474A1 (fr) | 2015-06-29 | 2017-01-04 | Evonik Degussa GmbH | Procédé de détection d'entérite nécrotique aviaire |
US20180066262A1 (en) | 2015-03-09 | 2018-03-08 | Caris Science, Inc. | Oligonucleotide probes and uses thereof |
US10590425B2 (en) | 2015-06-29 | 2020-03-17 | Caris Science, Inc. | Therapeutic oligonucleotides |
WO2017019918A1 (fr) | 2015-07-28 | 2017-02-02 | Caris Science, Inc. | Oligonucléotides ciblés |
EP3165926A1 (fr) | 2015-11-06 | 2017-05-10 | Humanitas Mirasole S.p.A. | Procédé de caractérisation des microvésicules spécifiques de cellule |
CN106811428A (zh) * | 2015-11-30 | 2017-06-09 | 复旦大学 | 一种提取细菌外排膜囊泡的方法 |
RU2608509C1 (ru) * | 2016-02-11 | 2017-01-18 | Елена Сергеевна Кастарнова | Способ получения экзосом из крови |
WO2018057820A1 (fr) | 2016-09-21 | 2018-03-29 | Predicine, Inc. | Systèmes et procédés de détection combinée d'altérations génétiques |
US11702702B2 (en) | 2016-04-15 | 2023-07-18 | Predicine, Inc. | Systems and methods for detecting genetic alterations |
WO2017181183A1 (fr) | 2016-04-15 | 2017-10-19 | Exosome Diagnostics, Inc. | Détection par plasma d'acides nucléiques de kinase de lymphome anaplasique (alk) et de transcrits de fusion d'alk et leurs utilisations dans le diagnostic et le traitement du cancer |
ES2908932T3 (es) | 2016-05-05 | 2022-05-04 | Exosome Diagnostics Inc | Perfilado de ácidos nucleicos de microvesícula y usos del mismo como características distintivas en diagnóstico de rechazo de trasplante renal |
WO2017197399A1 (fr) | 2016-05-13 | 2017-11-16 | Exosome Diagnostics, Inc. | Procédés automatisés et manuels pour l'isolement de vésicules extracellulaires et l'isolement conjoint d'adn acellulaire à partir de bioliquides |
EP3467059B1 (fr) | 2016-05-24 | 2022-02-23 | Japanese Foundation For Cancer Research | Procédé de récupération de vésicules extracellulaires et récipient destiné à des vésicules extracellulaires |
US11299733B2 (en) | 2016-07-15 | 2022-04-12 | University Of Massachusetts | Process of delivering small RNAs to sperm |
IL247368A0 (en) | 2016-08-18 | 2016-11-30 | Yeda Res & Dev | Diagnostic and therapeutic uses of exosomes |
JP2019535307A (ja) | 2016-10-21 | 2019-12-12 | エクソサム ダイアグノスティクス,インコーポレイティド | エキソソーム結合型核酸の配列決定および分析 |
AU2017366813B2 (en) | 2016-11-30 | 2023-04-20 | Exosome Diagnostics, Inc. | Methods and compositions to detect mutations in plasma using exosomal RNA and cell free DNA from non-small cell lung cancer patients |
JP7376091B2 (ja) * | 2016-12-23 | 2023-11-08 | エクソファーマ リミテッド | 微小胞およびエキソソームの精製または単離のための方法および組成物 |
WO2018126278A2 (fr) | 2017-01-02 | 2018-07-05 | Exosome Diagnostics, Inc. | Procédés de distinction d'arn et d'adn dans une préparation combinée |
KR101875594B1 (ko) * | 2017-01-13 | 2018-07-06 | ㈜로제타엑소좀 | 금속을 이용한 세포밖 소포체의 분리 방법 |
MX2019013377A (es) | 2017-05-12 | 2020-09-21 | Evonik Operations Gmbh | Procedimiento de detección de enfermedades inducidas por c. perfringens en animales. |
CN110945145A (zh) | 2017-05-17 | 2020-03-31 | 外来体诊断公司 | 微泡核酸和/或蛋白及其作为肾移植排斥的标志物的应用 |
US11899024B2 (en) | 2017-07-12 | 2024-02-13 | Exosome Diagnostics, Inc. | Treatment and diagnosis of parkinson's disease using isolated and enriched populations of biofluid-derived extracellular vesicles |
EP3655531A4 (fr) | 2017-07-18 | 2021-09-08 | Exosome Diagnostics, Inc. | Séquençage d'acides nucléiques associés à l'isolement exosomal chez des patients atteints de glioblastome multiforme |
EP3660142A4 (fr) * | 2017-07-26 | 2021-05-05 | Rosetta Exosome | Procédé d'isolement de vésicules extracellulaires à l'aide de cations |
TR201716062A2 (tr) * | 2017-10-18 | 2019-05-21 | Tuerkiye Bilimsel Ve Teknolojik Arastirma Kurumu Tuebitak | Bi̇r eksozomal terapöti̇k taşiyici üreti̇m yöntemi̇ ve bu yönteme uygun bi̇r şeki̇lde elde edi̇len bi̇r eksozomal terapöti̇k taşiyici |
EP3707278A1 (fr) | 2017-11-09 | 2020-09-16 | Alnylam Pharmaceuticals Inc. | Dosages et procédés de détermination de l'expression du gène lect2 |
WO2019104169A1 (fr) * | 2017-11-21 | 2019-05-31 | Purina Animal Nutrition Llc | Procédés de purification d'exosomes |
EP3752833A4 (fr) | 2018-02-15 | 2021-11-24 | Yeditepe Universitesi | Procédé d'isolement d'exosomes par un système de fluide à deux phases |
US20200378932A1 (en) * | 2018-02-20 | 2020-12-03 | Korea University Research And Business Foundation | Multi-column for isolating exosomes and exosome isolation method |
EP3802884A1 (fr) | 2018-06-06 | 2021-04-14 | Exosome Diagnostics, Inc. | Procédés de développement de biomarqueurs urinaires et de détection du cancer de la vessie |
CN108841777A (zh) * | 2018-06-22 | 2018-11-20 | 北京恩泽康泰生物科技有限公司 | 基于静电吸附的胞外囊泡及其内含物的提取方法及装置 |
CN112805562A (zh) * | 2018-07-31 | 2021-05-14 | 国立大学法人三重大学 | 外泌体的制造方法 |
WO2020106853A1 (fr) | 2018-11-20 | 2020-05-28 | Exosome Diagnostics, Inc. | Compositions et procédés de témoins internes d'isolements de microvésicules |
IT201800021226A1 (it) | 2018-12-27 | 2020-06-27 | Supsi Scuola Univ Professionale Della Svizzera Italiana | Processo e dispositivo per produrre esosomi |
CN109856259A (zh) * | 2018-12-29 | 2019-06-07 | 南通大学附属医院 | 一种血清胰腺癌外泌体特异蛋白及其再验证过程 |
KR102212465B1 (ko) * | 2019-01-16 | 2021-02-03 | 서울시립대학교 산학협력단 | 알엔에이 나노입자 전달을 통한 소포체의 제조방법 및 이로부터 제조된 소포체 |
CN109825472A (zh) * | 2019-03-01 | 2019-05-31 | 易春 | 一种细胞外囊泡的提取方法及试剂盒 |
US20230135456A1 (en) | 2020-04-13 | 2023-05-04 | Exoprother Medical Ltd. | Cell-derived vesicles comprising wild-type p53 protein for antiviral therapy |
US20210322483A1 (en) | 2020-04-16 | 2021-10-21 | Ichilov Tech Ltd. | Cell-derived particles presenting heterologous cd24 and use thereof in therapy |
IL277743A (en) | 2020-10-01 | 2022-04-01 | Yeda Res & Dev | A method for diagnosing breast cancer |
KR20220097337A (ko) * | 2020-12-30 | 2022-07-07 | 한국과학기술원 | 엑소좀 분리용 조성물 및 이를 이용한 엑소좀 분리 방법 |
JP2023104650A (ja) * | 2022-01-18 | 2023-07-28 | ダイセン・メンブレン・システムズ株式会社 | 細胞外小胞の分離精製方法 |
WO2024024336A1 (fr) * | 2022-07-28 | 2024-02-01 | 株式会社ダイセル | Dispositif de purification et de concentration d'un liquide comprenant une substance utile infime et procédé de production d'un liquide purifié et concentré d'une substance utile infime l'utilisant |
CN117070450B (zh) * | 2023-10-12 | 2024-01-16 | 哈药集团生物工程有限公司 | 一种外泌体的纯化方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997005900A1 (fr) * | 1995-08-03 | 1997-02-20 | Rijksuniversiteit Te Leiden | Vesicules presentant des antigenes obtenues a partir de cellules |
FR2766205A1 (fr) * | 1997-07-16 | 1999-01-22 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2877160B2 (ja) * | 1987-07-29 | 1999-03-31 | ザ リポソーム カンパニー,インコーポレイテッド | 粒子のサイズによる分離方法 |
US6165785A (en) * | 1996-05-24 | 2000-12-26 | University Of Cincinnati | Bone marrow cultures for developing suppressor and stimulator cells for research and therapeutic applications |
AU2710897A (en) * | 1996-05-31 | 1998-01-05 | Whitaker Corporation, The | Rechargeable battery connector |
-
1999
- 1999-01-27 FR FR9900886A patent/FR2788780B1/fr not_active Expired - Fee Related
-
2000
- 2000-01-19 CA CA002360752A patent/CA2360752A1/fr not_active Abandoned
- 2000-01-19 JP JP2000595691A patent/JP2002535665A/ja active Pending
- 2000-01-19 EA EA200100819A patent/EA003235B1/ru not_active IP Right Cessation
- 2000-01-19 IL IL14369200A patent/IL143692A0/xx unknown
- 2000-01-19 US US09/890,319 patent/US6899863B1/en not_active Expired - Fee Related
- 2000-01-19 EP EP00900609A patent/EP1143982A2/fr not_active Withdrawn
- 2000-01-19 AU AU30561/00A patent/AU768322B2/en not_active Ceased
- 2000-01-19 WO PCT/FR2000/000105 patent/WO2000044389A2/fr not_active Application Discontinuation
- 2000-01-19 CN CN00802903A patent/CN1355704A/zh active Pending
-
2002
- 2002-04-17 HK HK02102905.8A patent/HK1042647A1/zh unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997005900A1 (fr) * | 1995-08-03 | 1997-02-20 | Rijksuniversiteit Te Leiden | Vesicules presentant des antigenes obtenues a partir de cellules |
FR2766205A1 (fr) * | 1997-07-16 | 1999-01-22 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
WO1999003499A1 (fr) * | 1997-07-16 | 1999-01-28 | Institut National De La Sante Et De La Recherche Medicale | Vesicule cellulaire denommee ''exosome'', leur preparation et utilisation dans la stimulation d'une reponse immunitaire |
Non-Patent Citations (1)
Title |
---|
G. RAPOSO ET AL.: "B LYMPHOCYTES SECRETE ANTIGEN-PRESENTING VESICLES." JOURNAL OF EXPERIMENTAL MEDICINE, vol. 183, mars 1996 (1996-03), pages 1161-1172, XP002060486 NEW YORK, N.Y., US cité dans la demande * |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003016522A2 (fr) | 2001-08-17 | 2003-02-27 | Anosys, Inc. | Procedes et composes pour le ciblage de proteines vers des exosomes |
EP1766053A2 (fr) * | 2004-06-02 | 2007-03-28 | Sourcepharm, Inc. | Microvesicules contenant de l'arn et methodes associees |
EP1766053A4 (fr) * | 2004-06-02 | 2007-12-12 | Sourcepharm Inc | Microvesicules contenant de l'arn et methodes associees |
WO2013079701A2 (fr) | 2011-11-30 | 2013-06-06 | University Of Bremen | Expression d'arnmi dans le tissu placentaire |
EP3190186A2 (fr) | 2011-11-30 | 2017-07-12 | Jörn Bullerdiek | Expression des miarn dans le tissu placentaire |
EP4349343A2 (fr) | 2011-11-30 | 2024-04-10 | Jörn Bullerdiek | Expression des miarn dans le tissu placnetaire |
US11369634B2 (en) | 2012-08-15 | 2022-06-28 | The University Of Chicago | Exosome-based therapeutics against neurodegenerative disorders |
US10231997B2 (en) | 2012-08-15 | 2019-03-19 | The University Of Chicago | Exosome-based therapeutics against neurodegenerative disorders |
CN108025027B (zh) * | 2015-06-12 | 2022-05-24 | 哈德逊医学研究中心 | 一种治疗方法 |
CN108025027A (zh) * | 2015-06-12 | 2018-05-11 | 哈德逊医学研究中心 | 一种治疗方法 |
WO2017149118A1 (fr) | 2016-03-03 | 2017-09-08 | Institut Gustave Roussy | Vaccins à base de pioneer translation products (ptp) contre le cancer |
WO2019081474A1 (fr) * | 2017-10-24 | 2019-05-02 | Evox Therapeutics Limited | Purification par affinité de vésicules extracellulaires modifiées |
EP4112080A1 (fr) | 2017-10-24 | 2023-01-04 | Evox Therapeutics Limited | Purification d'affinité de vésicules extracellulaires modifiées |
US11975070B2 (en) | 2017-10-24 | 2024-05-07 | Evox Therapeutics Ltd | Affinity purification of engineered extracellular vesicles |
WO2019238626A1 (fr) | 2018-06-12 | 2019-12-19 | Evox Therapeutics Ltd | Ingénierie de vésicules extracellulaires pour une purification par affinité |
WO2022003206A1 (fr) | 2020-07-03 | 2022-01-06 | Evox Therapeutics Ltd | Vésicules extracellulaires à demi-vie améliorée |
WO2022229220A1 (fr) | 2021-04-26 | 2022-11-03 | Evox Therapeutics Limited | Vésicules extracellulaires (ev) modifiées à demi-vie améliorée |
Also Published As
Publication number | Publication date |
---|---|
FR2788780B1 (fr) | 2001-03-30 |
EA200100819A1 (ru) | 2001-12-24 |
CN1355704A (zh) | 2002-06-26 |
HK1042647A1 (zh) | 2002-08-23 |
AU3056100A (en) | 2000-08-18 |
EA003235B1 (ru) | 2003-02-27 |
JP2002535665A (ja) | 2002-10-22 |
US6899863B1 (en) | 2005-05-31 |
CA2360752A1 (fr) | 2000-08-03 |
IL143692A0 (en) | 2002-04-21 |
FR2788780A1 (fr) | 2000-07-28 |
WO2000044389A3 (fr) | 2000-11-16 |
AU768322B2 (en) | 2003-12-11 |
EP1143982A2 (fr) | 2001-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000044389A2 (fr) | Procede de preparation de vesicules membranaires | |
EP1155120B1 (fr) | Procede d'obtention d'une preparation virale purifiee | |
Lamparski et al. | Production and characterization of clinical grade exosomes derived from dendritic cells | |
CN112805562A (zh) | 外泌体的制造方法 | |
Yakubovich et al. | Principles and problems of exosome isolation from biological fluids | |
Sharif et al. | The effect of growth stage and isolation method on properties of ClearColi™ outer membrane vesicles (OMVs) | |
WO2017064294A1 (fr) | Procede de production de proteines erythrocytaires | |
Rao et al. | High resolution protein separations using affinity ultrafiltration with small charged ligands | |
JP5172864B2 (ja) | 抗腫瘍ワクチン、抗腫瘍ワクチンの調製方法及び抗腫瘍免疫療法の実行方法 | |
Silva et al. | Anion exchange chromatography-based platform for the scalable purification of extracellular vesicles derived from human mesenchymal stromal cells | |
Bueno et al. | In vitro removal of human IgG by pseudobiospecific affinity membrane filtration on a large scale. A preliminary report | |
EP0108658A1 (fr) | Dispositif pour l'élimination ou la récupération d'anticorps ou d'antigènes à partir du sang, son obtention et son utilisation | |
CN112760292A (zh) | 一种嵌合抗原受体纳米抗体外泌体及其纯化方法 | |
EP1697502A2 (fr) | Methodes d identification et de preparation de lymphocytes t regulateurs/suppresseurs, compositions et utilisations | |
Ventura et al. | In vitro removal of human IgG autoantibodies by affinity filtration using immobilized l-histidine onto PEVA hollow fiber membranes | |
EP2374470A1 (fr) | Utilisation thérapeutique de la protéine Beta2m | |
EP3291906B1 (fr) | Procede pour la purification du sang total ou d'un produit issu du sang | |
RU2622005C2 (ru) | СПОСОБ ПОЛУЧЕНИЯ СЕЛЕКТИВНОГО ИММУНОСОРБЕНТА ДЛЯ УДАЛЕНИЯ АНТИТЕЛ-IgG К ДЕСМОГЛЕИНУ 3 ТИПА ИЗ СЫВОРОТКИ КРОВИ БОЛЬНЫХ ПУЗЫРЧАТКОЙ | |
Tidke et al. | BIOGENESIS, METHOD OF ISOLATION AND CHARACTERISTICS OF EXOSOMES | |
US20180280444A1 (en) | Nanoparticle based tumor endothelial targeting vaccine | |
US20210128638A1 (en) | Cellular, organ, and whole-body rejuvenation utilizing cord blood plasma and pterostilbene | |
EP0273811B1 (fr) | Procédé de préparation d'un vaccin contre l'hépatite B | |
FR2819263A1 (fr) | Procede de maturation des cellules dendritiques et d'activation des macrophages avec le ru 41740 | |
US5994509A (en) | Method for obtaining uniform fractions of hyperpolymeric hemoglobins | |
JP2023150539A (ja) | 単離エクソソームを含む組成物及びその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 00802903.2 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 143692 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 30561/00 Country of ref document: AU Ref document number: 2000900609 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2000 595691 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2360752 Country of ref document: CA Ref document number: 2360752 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09890319 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200100819 Country of ref document: EA |
|
WWP | Wipo information: published in national office |
Ref document number: 2000900609 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 30561/00 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000900609 Country of ref document: EP |